儿童脓毒性休克:第5百分位与第50百分位平均动脉压目标的随机对照试验
该单中心、开放标签、随机非劣效性试验在印度一家三级PICU进行(2021年4月至2024年3月),纳入1月龄至16岁、液体复苏无反应且需血管升压药的脓毒性休克患儿144例,随机分为第5百分位或第50百分位平均动脉压目标组,据此调整血管升压药。主要终点28天全因死亡率两组无显著差异:第5百分位组16.9%(12/71) vs 第50百分位组23.2%(17/73)(P=0.41;风险差6.3;95%CI -6.9至19.2)。第50百分位组去甲肾上腺素使用率更高(85% vs 67%;P=0.04)、血管活性药物持续时间更长(30.4±13.3 vs 18.8±10.8;P=0.001)、血管活性-正性肌力评分更高(64.0±35.7 vs 45.2±29.6;P=0.001)、ARDS患病率更高(32.8% vs 16.9%;P=0.02)。作者认为较低血压目标可能安全,可减少血管活性药物使用及相关副作用。
要点
- 儿童脓毒性休克以第5百分位平均动脉压为目标与第50百分位相比,28天死亡率无显著差异(16.9% vs 23.2%;P=0.41)。
- 第50百分位组去甲肾上腺素使用率更高(85% vs 67%;P=0.04),血管活性药物持续时间更长(30.4±13.3 vs 18.8±10.8;P=0.001)。
- 第50百分位组血管活性-正性肌力评分更高(64.0±35.7 vs 45.2±29.6;P=0.001),ARDS患病率更高(32.8% vs 16.9%;P=0.02)。
- 两组在PICU/住院时间、机械通气时长、连续肾脏替代治疗需求及血管升压药相关不良事件方面无显著差异。
- 作者认为较低血压目标可能安全,可减少血管活性药物使用及相关副作用。
适用人群与场景
- 1月龄至16岁脓毒性休克患儿,液体复苏无反应且需血管升压药。
- 研究在印度一家三级PICU进行,时间为2021年4月至2024年3月。
处置流程与药物剂量
- 将患儿随机分配至第5百分位或第50百分位平均动脉压目标组,据此调整血管升压药治疗以维持目标血压。
研究设计与关键结果
- 单中心、开放标签、随机非劣效性试验,纳入144例脓毒性休克患儿,第5百分位组71例、第50百分位组73例。
- 主要终点28天全因死亡率:第5百分位组16.9%(12/71) vs 第50百分位组23.2%(17/73),P=0.41;风险差6.3;95%CI -6.9至19.2。
- 去甲肾上腺素使用率:第5百分位组67% vs 第50百分位组85%,P=0.04。
- 血管活性药物持续时间:第5百分位组18.8±10.8 vs 第50百分位组30.4±13.3,P=0.001。
- 血管活性-正性肌力评分:第5百分位组45.2±29.6 vs 第50百分位组64.0±35.7,P=0.001。
- ARDS患病率:第5百分位组16.9% vs 第50百分位组32.8%,P=0.02。
- PICU/住院时间、机械通气时长、连续肾脏替代治疗需求及血管升压药相关不良事件两组无显著差异。
证据类型、等级与局限
- 证据类型:单中心、开放标签、随机非劣效性试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于液体复苏无反应且需血管升压药的脓毒性休克患儿,以第5百分位平均动脉压为目标与第50百分位相比28天死亡率无显著差异,且血管活性药物用量及相关副作用更少;作者认为较低血压目标可能安全。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Hypotension is common in septic children, mean blood pressure (MBP) guides vasoactive agent titration. However, the Surviving Sepsis Guidelines for children were unable to recommend whether to target the 5th or 50th MBP percentile for septic shock. We aim to compare two MBP targets (5th vs. 50th percentile) for titrating vasoactive agents in septic shock patients.
DESIGN: Single-center, open-label, randomized noninferiority trial.
SETTING: It was conducted in a tertiary care PICU in India from April 2021 to March 2024.
PATIENTS: Patients 1 month to 16 years old with septic shock unresponsive to fluids and requiring vasopressors.
INTERVENTIONS: Children with septic shock were randomly assigned to either the 5th or 50th percentile MBP group, with vasopressor treatment adjusted to maintain the target blood pressure (BP) for each group.
MEASUREMENTS AND MAIN RESULTS: The primary outcome was 28-day all-cause mortality. Secondary outcomes included PICU/hospital stay, duration of vasoactive use, vasopressor-related adverse events, need for continuous renal replacement therapy (CRRT), invasive ventilation, and prevalence of acute respiratory distress syndrome (ARDS). A total of 144 children were enrolled. At 28 days, mortality did not differ significantly between groups: 16.9% (12/71) in the 5th centile group vs. 23.2% (17/73) in the 50th centile group ( p = 0.41; risk difference, 6.3; 95% CI, -6.9 to 19.2). Norepinephrine use was higher in the 50th centile group (85% vs. 67%; p = 0.04). Vasoactive duration was longer in the 50th centile group (30.4 ± 13.3 vs. 18.8 ± 10.8; p = 0.001). The Vasoactive-Inotropic Score was also higher (64.0 ± 35.7 vs. 45.2 ± 29.6; p = 0.001). ARDS prevalence was significantly higher in the 50th centile group (32.8% vs. 16.9%; p = 0.02). No significant differences were found in other secondary outcomes like length of stay, ventilation duration, need for CRRT, or adverse events.
CONCLUSIONS: Targeting a lower MBP (5th vs. 50th centile) in septic shock showed no significant difference in 28-day mortality. This suggests a lower BP target may be safe, reducing vasoactive drug use and related side effects.
参考来源
- Shah S, Kaul A, Shiwarkar G, et al. Fifth Centile Versus 50th Centile Mean Blood Pressure Targets in Pediatric Septic Shock: A Randomized Controlled Trial. Crit Care Med. 2025. PMID: 40511998. doi:10.1097/CCM.0000000000006718
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。